Biocardia announces fda approval of ind application for allogeneic nk1r+ human mesenchymal stem cells for ischemic heart failure

Sunnyvale, calif.--( business wire )--biocardia, inc. [nasdaq: bcda], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced food and drug administration (fda) approval of its investigational new drug (ind) application to initiate a first-in-human phase i/ii clinical trial of its neurokinin-1 receptor positive (nk1r+) allogeneic human mesenchymal stem cell (msc) therapy for the treatment of patients with ischemic heart failure.
BCDA Ratings Summary
BCDA Quant Ranking